|By Marketwired .||
|May 2, 2014 07:00 AM EDT||
LYON, FRANCE -- (Marketwired) -- 05/02/14 -- Flamel Technologies (NASDAQ: FLML) will release financial results for the first quarter of fiscal year 2014 on Monday, May 12, 2014, before the market open. A conference call to discuss these results has been scheduled for Monday, May 12th at 10:00 a.m. ET. A question and answer period will follow management's prepared remarks.
To participate in the conference call, investors are invited to dial 888-542-1086 (U.S. and Canada) or +1-719-325-2109 (international). The conference ID number is 9667665. The conference call webcast may be accessed at www.flamel.com. The archived webcast of the conference call will be available for 90 days on Flamel's website.
About Flamel Technologies. Flamel Technologies SA's (NASDAQ: FLML) business model is to blend high-value internally developed products with its leading drug delivery capabilities. The Company has a proprietary pipeline of niche specialty pharmaceutical products, while its drug delivery platforms are focused on the goal of developing safer, more efficacious formulations of drugs to address unmet medical needs. Its partnered pipeline includes biological and chemical drugs formulated with its Medusa and Micropump® (and its applications to the development of liquid formulations, i.e. LiquiTime® and of abuse-deterrent formulations Trigger Lock) proprietary drug delivery platforms. Several Medusa-based products have been successfully tested in clinical trials. The Company has developed products and manufactures Micropump-based microparticles under FDA-audited GMP guidelines. Flamel Technologies has collaborations with a number of leading pharmaceutical and biotechnology companies, including GlaxoSmithKline (Coreg CR®, carvedilol phosphate). The Company is headquartered in Lyon, France and has operations in St. Louis, Missouri, USA, and manufacturing facilities in Pessac, France. Additional information may be found at www.flamel.com.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including certain plans, expectations, goals and projections regarding financial results, product developments and technology platforms. All statements that are not clearly historical in nature are forward-looking, and the words "anticipate," "assume," "believe," "expect," "estimate," "plan," "will," "may," and similar expressions are generally intended to identify forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks include risks that the continued integration of Éclat Pharmaceuticals may not be successful or that certain payment acceleration events may be triggered; the reacquisition of the exclusive rights to develop and commercialize IFN-β XL worldwide and identification of an alternative strategic partner for the program may not be successful; the identified opportunities will not result in shorter-term, high value results; clinical trial results may not be positive or our partners may decide not to move forward; products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements; products in development may not achieve market acceptance; competitive products and pricing may hinder our commercial opportunities; we may not be successful in identifying and pursuing opportunities to develop our own product portfolio using Flamel's technology; and the risks associated with our reliance on outside parties and key strategic alliances. These and other risks are described more fully in Flamel's Annual Report on Form 20-F for the year ended December 31, 2013 that has been filed with the Securities and Exchange Commission (SEC). All forward-looking statements included in this release are based on information available at the time of the release. We undertake no obligation to update or alter our forward-looking statements as a result of new information, future events or otherwise.
Dec. 8, 2016 09:45 PM EST Reads: 1,233
Dec. 8, 2016 09:15 PM EST Reads: 1,667
Dec. 8, 2016 09:15 PM EST Reads: 951
Dec. 8, 2016 08:30 PM EST Reads: 1,885
Dec. 8, 2016 07:45 PM EST Reads: 319
Dec. 8, 2016 07:15 PM EST Reads: 379
Dec. 8, 2016 06:45 PM EST Reads: 951
Dec. 8, 2016 05:45 PM EST Reads: 948
Dec. 8, 2016 05:45 PM EST Reads: 1,720
Dec. 8, 2016 05:00 PM EST Reads: 1,820
Dec. 8, 2016 04:45 PM EST Reads: 1,847
Dec. 8, 2016 04:45 PM EST Reads: 2,253
Dec. 8, 2016 04:30 PM EST Reads: 394
Dec. 8, 2016 04:30 PM EST Reads: 1,973
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor - all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
Dec. 8, 2016 04:15 PM EST Reads: 313